ADLANTE(Lenvatinib)
Therapeutic class: Kinase Inhibitors
- Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
- Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
- For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
10 mg & 4 mg
10 mg:-
A strip of 10 Capsules4 mg:-
A strip of 10 Capsules- 20°C to 25°C (68°F to 77°F) , Shelf Life: 2 Years
- As directed by physician
